MRNS — Marinus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $30.34m
- $43.35m
- $30.99m
Brief: Marinus Pharmaceuticals Receives FDA Orphan Drug Designation For Ganaxolone In The Treatment Of Lennox-Gastaut Syndrome
Brief: Marinus Pharmaceuticals Inc Does Not Hold Cash Deposits Or Securities At Silicon Valley Bank
U.S. RESEARCH ROUNDUP-Tesla, Oracle, Caredx
Marinus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Marinus Pharmaceuticals Reports Q4 And Full Year 2022 Financial Results
Marinus Pharmaceuticals Inc expected to post a loss of 70 cents a share - Earnings Preview
Brief: Marinus Pharmaceuticals To Provide Business Update And Report Fourth Quarter 2022 Financial Results On March 7, 2023
Brief: Marinus Pharmaceuticals Board Increased Size Of Board From Six To Seven Members
Brief: Marinus Pharmaceuticals Appoints Christine Silverstein To Its Board Of Directors
U.S. STOCKS ON THE MOVE-Eli Lilly, Tesla, Kohl's, Ally Financial
Marinus surges as RBC sees main drug as positive cash flow contributor by 2024
U.S. STOCKS ON THE MOVE-Netflix, PagerDuty, Proterra
U.S. STOCKS ON THE MOVE-Biogen, Wayfair, Costco
Marinus surges as RBC sees main drug as positive cash flow contributor by 2024
Brief: Marinus Pharmaceuticals Reports Preliminary Fourth Quarter And Full Year 2022 Ztalmy® Net Product Revenue And Provides Business Update
Brief: Marinus Pharmaceuticals Announces Collaboration With Tenacia Biotechnology For Ganaxolone Development And Commercialization In China
Brief: Marinus Pharmaceuticals Appoints CEO Scott Braunstein As Chairman Of The Board
U.S. STOCKS ON THE MOVE-Gold, silver, and copper miners
U.S. STOCKS ON THE MOVE-Skywater Technology, First Advantage, solar stocks